Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells

Clinical and Experimental Immunology

Volumn 170, Issue 1, 2012, Pages 94-100

  Nakano, M ^a   Fujii, T ^a   Hashimoto, M ^a   Yukawa, N ^a   Yoshifuji, H ^a   Ohmura, K ^a   Nakaizumi, A ^a   Mimori, T ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

CCL5 (RANTES); Connective tissue disease; CX3CL1 (fractalkine); Pulmonary vascular disease; Type I interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; FRACTALKINE; INTERFERON; JANUS KINASE INHIBITOR; MESSENGER RNA; RANTES;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PULMONARY VASCULAR DISEASE; T LYMPHOCYTE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; CHEMOKINE CCL5; CHEMOKINE CX3CL1; CONNECTIVE TISSUE DISEASES; ENDOTHELIAL CELLS; ENZYME INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; INTERFERON-ALPHA; INTERFERON-BETA; JANUS KINASES; MICROSCOPY, FLUORESCENCE;

EID: 84865619532     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04638.x     Document Type: Article

References (39)

1. Borden EC, Sen GC, Uze G etal. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-90.
2. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43:1431-42.
3. Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54:408-20.
4. Eloranta ML, Franck-Larsson K, Lovgren T etal. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69:1396-402.
5. Dhillon S, Kaker A, Dosanjh A etal. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010; 55:1785-90.
6. Ledinek AH, Jazbec SS, Drinovec I etal. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler 2009; 15:885-6.
7. Sanchez O, Marcos E, Perros F etal. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007; 176:1041-7.
8. Dorfmüller P, Zarka V, Durand-Gasselin I etal. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:534-9.
9. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:1419-25.
10. Fong AM, Robinson LA, Steeber DA etal. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188:1413-9.
11. Imai T, Hieshima K, Haskell C etal. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-30.
12. Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000; 275:34183-9.
13. Ancuta P, Rao R, Moses A etal. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197:1701-7.
14. Thieblemont N, Weiss L, Sadeghi HM etal. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 1995; 25:3418-24.
15. Belge KU, Dayyani F, Horelt A etal. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168:3536-42.
16. Bazan JF, Bacon KB, Hardiman G etal. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385:640-4.
17. Harrison JK, Jiang Y, Wees EA etal. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol 1999; 66:937-44.
18. Matsumiya T, Imaizumi T, Fujimoto K etal. Soluble interleukin-6 receptor alpha inhibits the cytokine-induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 2001; 269:35-41.
19. Hasegawa M, Sato S, Echigo T etal. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005; 64:21-8.
20. Marasini B, Cossutta R, Selmi C etal. Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin Dev Immunol 2005; 12:275-9.
21. Chandrasekar B, Mummidi S, Perla RP etal. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003; 373:547-58.
22. Perros F, Dorfmüller P, Souza R etal. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29:937-43.
23. Pietra GG, Capron F, Stewart S etal. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43:S25-S32.
24. Yajima N, Kasama T, Isozaki T etal. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005; 52:1670-5.
25. Vallin H, Blomberg S, Alm GV etal. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115:196-202.
26. Lenert P. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol 2010; 161:208-22.
27. Shah D, Wanchu A, Bhatnagar A. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 2011; 216:1010-7.
28. Swanson BJ, Murakami M, Mitchell TC etal. RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR-dependent process. Immunity 2002; 17:605-15.
29. Fleischmann R, Cutolo M, Genovese MC etal. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64:617-29.
30. Thompson JE, Cubbon RM, Cummings RT etal. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002; 12:1219-23.
31. Krishnaswamy G, Smith JK, Mukkamala R etal. Multifunctional cytokine expression by human coronary endothelium and regulation by monokines and glucocorticoids. Microvasc Res 1998; 55:189-200.
32. Buttmann M, Goebeler M, Toksoy A etal. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol 2005; 168:175-82.
33. Salcedo R, Ponce ML, Young HA etal. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96:34-40.
34. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32.
35. Leaman DW, Chawla-Sarkar M, Jacobs B etal. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-β compared with IFN-α2. J Interferon Cytokine Res 2003; 23:745-56.
36. van Boxel-Dezaire AHH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006; 25:361-72.
37. Thomas C, Moraga I, Levin D etal. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011; 146:621-32.
38. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
39. Thomas KE, Galligan CL, Newman RD etal. Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J Biol Chem 2006; 281:31119-30.